Este protocolo aborda las lesiones de dermatitis atópica (DA) localizada que permanecen sin control a pesar de un régimen tópico de primera línea, y define el siguiente paso clínico cuando no se ha alcanzado la respuesta esperada.
El tratamiento previo —un corticosteroide tópico o un inhibidor de calcineurina tópico (pimecrolimus o tacrolimus)— debía producir una mejora medible en 2 a 6 semanas. Cuando esa respuesta no se alcanza, este protocolo es aplicable.
Objetivo clínico: Resolución rápida de las lesiones de dermatitis atópica localizada refractarias al tratamiento tópico estándar.
DOI: 10.1016/j.anai.2023.11.009
In patients with localized uncontrolled atopic dermatitis refractory to mid-high−potency topical treatment (US classes 2–5 or tacrolimus), the JTF panel suggests addition of a time and body area-limited (eg, 4–7 days; minimum 1 hour to maximum overnight, once per day) trial of occlusive low-mid−potency topical corticosteroid (US classes 3–7) therapy over continued standard topical therapy alone (conditional recommendation, very low-certainty evidence).
Experiential evidence from patients and clinicians suggested that, when used judiciously for specific, local treatment of lesions in a time-limited fashion, most patients experience rapid resolution of AD lesions refractory to corresponding topical treatment without temporary occlusion.
View source ↗